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Abstract
Background: Colorectal cancer (CRC) is one of the most common malignancies and a leading cause of cancer
death worldwide. Most cancer cells display high rates of glycolysis with production of lactic acid, which is then
exported to the microenvironment by monocarboxylate transporters (MCTs). The main aim of this study was to
evaluate the significance of MCT expression in a comprehensive series of primary CRC cases, lymph node and
hepatic metastasis.
Methods: Expressions of MCT1, MCT4, CD147 and GLUT1 were studied in human samples of CRC, lymph node and
hepatic metastasis, by immunohistochemistry.
Results: All proteins were overexpressed in primary CRC, lymph node and hepatic metastasis, when compared with
non-neoplastic tissue, with exception of MCT1 in lymph node and hepatic metastasis. MCT1 and MCT4 expressions
were associated with CD147 and GLUT1 in primary CRC. These markers were associated with clinical pathological
features, reflecting the putative role of these metabolism-related proteins in the CRC setting.
Conclusion: These findings provide additional evidence for the pivotal role of MCTs in CRC maintenance and
progression, and support the use of MCTs as biomarkers and potential therapeutic targets in primary and metastatic
CRC.
Keywords: Colorectal cancer, Lymph node metastasis, Hepatic metastasis, Monocarboxylate transporters, CD147,
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Background
Colorectal cancer (CRC) is the third most common can-
cer in men and the second in women, being one of the
most prevalent diseases of the occidental world [1].
Altered metabolism in cancer cells was recently recog-
nized as a hallmark of cancer [2]. Most cancer cells display
high rates of glycolysis with production of lactic acid,
which is then exported to the microenvironment, leading
to a decrease in extracellular pH. High levels of lactate and
low pH has been associated with increased malignant fea-
tures, including cell invasion [3], suppression of immune
response [4] tumour proliferation, angiogenesis and metas-
tasis [5, 6]. Extracellular lactate has been associated with
poor prognosis in cancer [6, 7] and monocarboxylate trans-
porters (MCTs) are essential players in the maintenance of
the glycolytic metabolism being both lactate transporters
and pH regulators [8–11]. MCTs are currently seen as
promising therapeutic targets in cancer, with encouraging
results in vitro and in vivo models [12–21].
The MCT family comprises 14 members; however, only
the first four (MCT1-4) were identified as mediating the
proton-coupled transport of monocarboxylic acids across
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the plasma membrane [22–24]. It is currently believed
that the MCT isoform 4 mediates mostly lactate efflux,
whereas MCT1 performs the uptake of lactate that is
used by oxidative cancer cells [17, 25, 26]. CD147 is co-
expressed with MCT1 and MCT4 for proper plasma
membrane expression and catalytic activity [27–30].
Data on the role of MCTs in CRC is somewhat contra-
dictory. Koukoukaris et al. [31] described MCT1 and
MCT2 expression in cancer cells and tumour-associated
fibroblasts, with weak MCT4 expression in the tumour
stroma. On the other hand, our group described higher
MCT1 and MCT4 CRC membrane expression and lower
of MCT2 expression, comparing with the adjacent
normal tissue [32]. However, despite these controversies,
positive MCT4 expression in CRC has been associated
with poor prognosis [33, 34], supporting the role of this
MCT isoform in CRC malignancy. Interestingly, the
expression of MCT1 and MCT4 is described to vary
along tumor progression, especially for MCT1. There
are reports showing decrease in MCT1 expression during
transition from normality to malignancy in the colonic
mucosa [35, 36]. However, upregulation of MCT1 has also
been described in advanced CRC tumors [31, 32]. Besides
MCTs, lactate can be also transported by sodium-coupled
monocarboxylate co-transporters (SMCTs), which are
expressed in the apical membrane of colon [37–39]. How-
ever, SMCT1 expression is frequently silenced in aberrant
colon precursor lesions and cancer [40, 41].
The aim of the present study was to evaluate the role of
MCTs in CRC, by assessing the immunohistochemical
expression of the MCT isoforms 1, 4, CD147 and the
glycolytic metabolic marker GLUT1, and correlate their
expressions with clinicopathological parameters in a
comprehensive CRC series, including primary tumours
and both lymph node and hepatic metastasis. Our results
provide additional evidence of MCTs role in primary CRC
and CRC metastasis, supporting their use as biomarkers
and potential therapeutic targets in primary and meta-
static CRC.
Methods
CRC primary tumour and metastasis human samples
Tissue samples and data from 487 patients treated in
Hospital de Braga, Portugal, between 1st January of 2005
and 1st January of 2010 with CRC diagnosis were col-
lected prospectively. Tumour localization was recorded
and classified as colon and rectum (between anal verge
and 15 cm at rigid rectoscopy). The histological type of
CRC was classified by an experienced pathologist and
tumour staging was graded according to the TNM classi-
fication, sixth edition [42]. Tissue samples of CRC lymph
node metastasis were selected from the previous series,
comprising 210 patients.
Additionally, an independent series of 45 patients with
histological diagnosis of CRC hepatic metastasis oper-
ated between 1st January of 2003 and 1st January of
2011 was retrieved from the files of Hospital de Braga
and data were retrospectively collected.
CRC samples and CRC lymph node metastasis were
included into tissue microarrays (TMAs). Prior to TMA
construction, haematoxylin and eosin sections were
reviewed to select representative areas of the tumour.
Normal-adjacent tissue was also included in the TMAs
for primary tumours. Each case was represented in the
TMA by at least two cores of 0.6 mm.
The study protocol was approved by the Ethics
Committee of Hospital de Braga. The data of CRC and
lymph node metastasis series were collected prospect-
ively, patients were informed and signed a written
consensus for collecting data and samples collection.
Immunohistochemistry
Protein expression in primary CRC samples, lymph
nodes and hepatic metastasis was evaluated by
Table 1 Detailed aspects of the immunocytochemical and immunohistochemical procedure used to visualize the different proteins
Protein Antigen retrieval Positive
Control
Peroxidase
inactivation
Detection system Antibody
Company Dilution Incubation
period
MCT1 Citrate buffer
(10 mM, pH = 6.0)
98 °C; 20 min.
Colon
carcinoma
0.3 % H2O2
in methanol,
30 min.
R.T.U. VECTASTAIN® Elite® ABC Kit
(Vector Laboratories)
Chemicon Ref. AB3538P 1:300 Overnight
MCT4 Citrate buffer
(10 mM, pH = 6.0)
98 °C; 20 min.
Colon carcinoma 3 % H2O2
in methanol,
30 min.
Ultravision Detection System
Anti-polyvalent, HRP
(Lab Vision Corporation)
Santa Cruz Biotechnology
Ref. sc-50329
1:200 2 h
CD147 EDTA (1 mM, pH = 8)
98 °C; 15 min.
Colon carcinoma 3 % H2O2 in
methanol,
10 min.
Ultravision Detection System
Anti-polyvalent, HRP
(Lab Vision Corporation)
Zymed Ref. 18-7344 1:500 2 h
GLUT1 Citrate buffer
(10 mM, pH = 6.0)
98 °C; 10 min.
Skin 3 % H2O2 in
methanol,
10 min.
Ultravision Detection System
Anti-polyvalent, HRP
(Lab Vision Corporation)
Abcam Ref. ab15309-500 1:500 2 h
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Fig. 1 Representative immunohistochemical expression of proteins in CRC NA tissue, CRC primary tumour, CRC lymph node metastasis and CRC
hepatic metastasis. Representative immunohistochemical expression of MCT1, MCT4, CD147 and GLUT1 in CRC NA tissue, CRC primary tumour
and CRC lymph node metastasis and CRC hepatic metastasis. (40x and 200x magnification)
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immunohistochemistry, as previously described [43]. De-
tailed information is depicted in Table 1. The specificity
of MCT1 and MCT4 antibodies has been demonstrated
in previous publications [19–21].
Immunohistochemical evaluation
Immunohistochemical evaluation was performed as pre-
viously described [32].
Briefly, sections were scored semi-quantitatively for im-
munoreaction extension (score 0–3) and intensity (score
0–3). Immunoreaction final score was defined as the sum
of both parameters, and grouped as negative (0–2) and
positive (≥3). Both cytoplasm and plasma membrane
staining were assessed, but for statistical analysis only
membrane staining was considered. Evaluation of protein
expressions was performed by blind analysis by two ob-
servers and discordant cases were discussed in a double-
head microscope in order to define the final score.
KRAS and BRAF mutation screening
Mutation analysis of BRAF (exon 15) and KRAS (codons
12 and 13) hotspot mutations, was performed by PCR,
using primers and methods previously described [44, 45],
followed by direct sequencing.
Microsatellite Instability analysis
Microsatellite Instability (MSI) was determined using a
multiplex PCR of five quasimonomorphic mononucleo-
tide repeat markers was end-labeled with a fluorescent
dye (NR27, NR21, NR24, BAT25 and BAT26), as de-
scribed [46]. PCR was performed using the Qiagen
Multiplex PCR Kit, and products were separated using
the ABI 3730 XL capillary genetic analyzer (Applied Bio-
systems) and analyzed using the GeneMapper 4.1 soft-
ware (Applied Biosystems). Cases exhibiting instability at
three or more markers were considered as having high
MSI (MSI-H), those with instability at one or two
markers being defined as having low MSI (MSI-L), and
those showing no instability were defined as microsatel-
lite stable (MSS), as described [47].
Statistical analysis
All data were analyzed using the Statistical Package for the
Social Sciences, version 19.0 (SPSS Inc., Chicago, Illinois,
Fig. 2 Frequency of protein staining in CRC NA tissue, CRC primary tumour and CRC lymph node and hepatic metastasis. Frequency of MCT1,
MCT4, CD147 and GLUT1 plasma membrane staining in CRC NA (normal adjacent) tissue, CRC primary tumour and CRC lymph node and hepatic
metastasis. *p≤ 0.05
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USA). Comparisons were examined for statistical signifi-
cance using Pearson’s chi-square (χ2) test and Fisher’s
exact test (when n < 5).
Expression differences between lymph node metasta-
sis and primary CRC were tested with McNemar test.
Survival curves were determined for overall survival by
the Kaplan–Meier method using log-rank test.
Predictive factors of prognosis were identified by means
of Cox proportional hazards regression models, which
were used to estimate hazard ratios (HR) and their 95 %
confidence intervals in univariate and multivariate ana-
lysis. For multivariate analysis, variables that reached a
p value <0.1 at univariate analysis were included. The
threshold for significant p values was established as
p ≤ 0.05.
Results
MCT4, CD147 and GLUT1 are overexpressed in CRC
primary tumours, lymph node and hepatic metastasis
To infer about the importance of the proteins MCT1,
MCT4, CD147 and GLUT1 in the progression of CRC,
their expression was evaluated by immunohistochemistry
in 487 samples of CRC, 210 samples of CRC lymph node
metastasis and 45 samples of hepatic metastasis. Repre-
sentative images of MCT1, MCT4, CD147 and GLUT1
positive staining in CRC normal adjacent (NA) epithelium,
primary tumour, lymph node and hepatic metastasis are
presented in Fig. 1.
All proteins were overexpressed at the plasma membrane
of primary CRC tumours, CRC lymph node metastasis and
CRC hepatic metastasis when compared with CRC NA
tissue (p < 0.001, Fig. 2), with exception for MCT1 in CRC
lymph node and hepatic metastasis. We detected a signifi-
cant increase in both MCT1 and MCT4 expressions in
CRC primary tumour (p < 0.001, for both), with a decrease
of MCT1 expression in CRC primary tumour to lymph
node and hepatic metastasis (p < 0.001, for both) and a
decrease of MCT4 expression in CRC primary tumour to
hepatic metastasis (p = 0.0001). Compared to the MCTs
expressions, the percentage of CD147 and GLUT1 positiv-
ity reactions were lower in CRC primary tumour; however,
there was an increase in their expression from CRC pri-
mary tumour to lymph node (p < 0.001 and p = 0.003,
respectively) and hepatic metastasis (p < 0.001, for both)
(Fig. 2). In the context of another study (yet unpublished),
we analyzed 45 samples of non-neoplastic lymph nodes
where we saw that all cases were negative for MCT1,
MCT2, MCT4 and CD147 and only one case was positive
for GLUT1 (2.2 %).
We also matched the expression of these metabolism-
related proteins in CRC hepatic metastasis with NA hep-
atic tissue, and we observed that these proteins presented
Table 2 Assessment of associations between protein plasma membrane expression in CRC primary tumour and in CRC lymph node
metastasis
LN_MCT1 p
MCT1 Negative Positive Total 0.000
(%) (%)
CRC_MCT1 Negative (%) 80 % (n = 8) 20,0 % (n = 2) 100 % (n = 10)
Positive (%) 69.5 % (n = 73) 30.5 % (n = 32) 100 % (n = 105)
Total 70.4 % (n = 81) 29.6 % (n = 34) 100 % (n = 115)
MCT4 LN_MCT4 p
Negative (%) Positive (%) Total 0.568
CRC_MCT4 Negative (%) 45.0 % (n = 18) 55.0 % (n = 22) 100 % (n = 40)
Positive (%) 40.3 % (n = 27) 59.7 % (n = = 40) 100 % (n = 67)
Total 100 % (n = 45) 100 % (n = 62) 100 % (n = 107)
CD147 LN_CD147 p
Negative (%) Positive (%) Total 0.000
CRC_CD147 Negative (%) 25.3 % (n = 20) 74.7 % (n = 59) 100.0 % (n = 79)
Positive (%) 14.7 % (n = 5) 85.3 % (n = 29) 100.0 % (n = 34)
Total 22.1 % (n = 25) 77.9 % (n = 88) 100.0 % (n = 113)
GLUT1 LN_GLUT1 p
Negative (%) Positive (%) Total 0.003
CRC_GLUT1 Negative (%) 55.6 % (n = 35) 44.4 % (n = 28) 100.0 % (n = 63)
Positive (%) 26.5 % (n = 9) 73.5 % (n = 25) 100.0 % (n = 34)
Total 45.4 % (n = 44) 54.6 % (n = 53) 100.0 % (n = 97)
CRC Colorectal cancer, LN Lymph node
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a low expression in the liver tissue (p < 0.001, for all pro-
teins, data not shown), namely MCT4 and GLUT1 with
no expression and MCT1 and CD147 with 64.4 and 30 %,
respectively, at NA hepatic tissue.
Since CRC primary tumours and lymph node metastasis
belong to the same group of patients, we could compare
the expression of the proteins in the two types of samples.
We observed that MCT1, CD147 and GLUT1 positivity in
CRC primary tumour samples associates with MCT1,
CD147 and GLUT1 positivity in their respective lymph
node metastasis (p < 0.001, p < 0.001 and p = 0.003
respectively). On the other hand, MCT4 expression in
lymph node metastasis seems to be independent of its
expression in CRC primary tumour. Interestingly, primary
CRC with negative MCT1 and MCT4 expressions can ori-
ginate lymph node metastasis with positive expression for
both markers. Detailed information is depicted in Table 2.
MCT1 and MCT4 expression is associated with CD147 and
GLUT1 in CRC primary tumour and in lymph node and
hepatic metastasis
To better characterize the role of MCT1 and MCT4 in
our samples, we assessed the association with their
chaperone CD147 and the glycolytic marker GLUT1.
MCT1 expression was associated with CD147 (p =
0.003) in CRC primary tumour samples and with
GLUT1 in CRC hepatic metastasis (p = 0.002) (Table 3).
The expression of MCT4 was associated with GLUT1
(p = 0.001) in CRC primary tumour and with CD147 ex-
pression (p = 0.050) (Table 3). MCT4 positivity was also
associated with CD147 and GLUT1 in CRC lymph node
metastasis samples (p = 0.007 and p = 0.019, respectively)
and hepatic metastasis samples (p = 0.019 and p < 0.001,
respectively) (Table 3).
MCT1, MCT4, CD147 and GLUT1 expressions are
associated with poor prognostic features
In order to assess the clinicopathological value of the ex-
pression of MCTs, CD147 and GLUT1, we sought for
associations with the clinicopathological data of CRC
primary tumours. The following associations were found:
positive association between MCT1 expression and older
patients (p = 0.007, Table 4); CD147 positivity and bigger
tumours and higher tumour penetration (p = 0.003, p =
0.034 Table 5); and GLUT1 with exophytic macroscopic
appearance and low CEA levels (p = 0.023 and p = 0.050
Table 3 Assessment of associations between MCTs and CD147/GLUT1 in CRC primary tumour and in CRC primary tumour and
metastasis
CRC primary tumour CD147 GLUT1
n Positive (%) p n Positive (%) p
MCT1
Positive 452 157 (34.7 %) 0.003 425 126 (29.6 %) 0.076
Negative 36 4 (11.1 %) 33 5 (15.2 %)
MCT4
Positive 269 100 (37.2 %) 0.050 262 90 (34.4 %) 0.001
Negative 203 58 (28.6 %) 191 38 (19.9 %)
CRC lymph node metastasis
MCT1
Positive 31 30 (96.8 %) 0.100 28 24 (85.7 %) 0.165
Negative 66 56 (84.8 %) 44 31 (70.5 %)
MCT4
Positive 56 54 (96.4 %) 0.007 46 39 (84.8 %) 0.019
Negative 39 30 (76.9 %) 25 15 (60.0 %)
CRC hepatic metastasis
MCT1
Positive 33 24 (72.7 %) 0.097 33 23 (69.7 %) 0.002
Negative 8 3 (37.5 %) 9 1 (11.1 %)
MCT4
Positive 18 16 (88.9 %) 0.019 18 18 (100 %) <0.001
Negative 25 13 (52.0 %) 25 6 (24.0 %)
CRC Colorectal cancer
Martins et al. BMC Cancer  (2016) 16:535 Page 6 of 15
respectively, Table 4), poorly differentiated tumours (p =
0.009, Table 5) and a trend to associate with the pres-
ence of lymph node metastasis (p = 0.058, Table 5). No
significant correlations were found among MCTs,
CD147 and GLUT1 and the molecular markers KRAS
or BRAF mutations and Microsatellite Instability status.
Assessment of associations between plasma membrane
protein expression in lymph node metastasis and clinico-
pathological data of CRC primary tumour revealed a sig-
nificant association between MCT4 and tumours
localized in colon (colon cancer (p = 0.032, Table 6) and
tumour penetration (p = 0.034, Table 7), and for CD147
positivity and tumour differentiation (p = 0.033, Table 7).
In CRC hepatic metastasis, we observed associations
between MCT1 and colon tumour localization (p = 0.022)
(Table 8).
Observing the influence of MCTs, CD147 and GLUT1
expressions in CRC survival curves assessed by log-rank
test, we found that positivity for MCT1 in the plasma
membrane associated with better cumulative survival in
CRC stage IV (p = 0.012) (Fig. 3), while no correlations
were found for the remaining proteins (Table 9). The
predictive prognostic value of MCT1 was analyzed by
means of Cox proportional hazards regression model,
however, multivariate analysis showed that only tumor
differentiation remains as an independent factor with
predictive value for overall survival (Table 10). No sig-
nificant differences were found in the CRC lymph node
and hepatic metastasis survival curves for the different
proteins.
Discussion
MCTs play an essential role in the maintenance of can-
cer glycolytic metabolism. On one hand, they perform
the efflux of lactate and, on the other hand, they help
in the regulation of the cell pH, by co-transporting a
proton [8, 13–15, 17, 18]. Due to their upregulation in
several cancers, they are currently seen as promising
therapeutic targets [8, 12–18], with an inhibitor of
MCT1 already in clinical trials (NCT01791595). Here
we aimed to characterize the expression of MCT1,
MCT4, CD147 and GLUT1 in a comprehensive series
of CRC primary tumours, lymph node and hepatic me-
tastasis, as well as to assess the clinical-pathological
significance of their overexpression.
Our group has previously analyzed the immunoexpres-
sion of MCT isoforms 1, 2 and 4 in a series of 126 cases
of CRC. Expression of all MCT isoforms in tumour cells
Table 4 Assessment of associations between proteins plasma membrane expression and clinical data in CRC primary tumours
MCT1 MCT4 CD147 GLUT1
n Positive (%) p n Positive (%) p n Positive (%) p n Positive (%) p
Sex
Male 314 92.7 0.934 302 57.3 0.801 312 31.4 0.391 294 28.6 0.969
Female 186 92.5 180 56.1 182 35.2 169 28.4
Age (years)
≤45 23 78.3 0.007 21 47.6 0.383 23 21.7 0.247 23 26.1 0.792
>45 477 93.3 461 57.3 471 33.3 440 28.6
Presentation
Asymptomatic 87 93.1 0.844 84 48.8 0.102 87 36.8 0.383 83 28.9 0.928
Symptomatic 413 92.5 398 58.5 407 31.9 380 28.4
Localization
Colon 360 92.5 0,891 351 59.3 0.080 359 33.4 0.625 338 29.3 0.541
Rectum 140 92.9 131 50.4 135 31.1 125 26.4
Macroscopic Appearence
Polypoid 254 92.9 0.492 247 54.7 0.245 249 33.3 0.798 239 23.8 0.023
Ulcerative 116 91.4 115 54.8 118 32.3 111 29.7
Infiltrative 42 85.7 40 62.5 40 27.5 35 25.7
Exophytic 42 95.2 37 70.3 41 29.3 34 50.0
Vilosous 2 100 2 100 2 0.0 2 0.0
CEA (ng/mL)
<5 122 90.2 0.568 115 60.0 0.665 118 33.1 0.455 111 36.9 0.05
≥5 272 91.9 269 57.6 270 29.3 256 22.7
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was significantly increased, with a significant gain in
membrane expression for MCT1 and MCT4 and loss
for MCT2 in tumour cells, when compared to adjacent
normal epithelium [32]. In the present study, we
strengthen the previous results by increasing the number
of primary CRC cases from 126 to 487 and also included
210 of lymph node metastasis of the same patients and
45 additional cases of CRC hepatic metastasis. We
Table 5 Assessment of associations between proteins plasma membrane expression and pathological data in CRC primary tumours
MCT1 MCT4 CD147 GLUT1
n Positive (%) p n Positive (%) p n Positive (%) p n Positive (%) p
Tumor size (cm)
≤4.5 286 93.4 0.389 278 54.7 0.265 283 27.9 0.003 267 29.6 0.466
>4.5 182 91.2 175 60.0 180 41.1 167 26.3
Histological Type
Adenocarcinoma 417 92.8 0.456 402 57.0 0.862 411 33.6 0.787 386 28.2 0.389
A. Mucinous 51 90.2 49 57.1 52 28.8 46 26.1
A. Invasive 24 95.8 24 54.2 23 26.1 23 39.1
Signet ring and mucinous 4 75.0 3 33.3 4 25.0 4 0.0
Differentiation
Well-differentiated 219 93.2 0.271 213 56.8 0.070 217 34.6 0.875 202 21.3 0.009
Moderately-differentiated 209 93.3 204 55.4 206 32.5 197 35.0
Poorly-differentiated 49 85.7 43 69.8 48 29.2 43 39.5
Undifferentiated 4 100.0 3 0.0 4 25.0 3 33.3
Tumour Penetration
Tis 5 100.0 0.946 6 16.7 0.277 4 25.0 0.034 5 0.0 0.436
T1 30 90.0 28 50.0 30 13.3 27 29.6
T2 59 93.2 58 56.9 59 30.5 55 21.8
T3 376 92.6 359 57.7 371 33.2 350 29.4
T4 24 91.7 25 64.0 24 54.2 20 35.0
Spread to lymph nodes
Absent 280 92.5 0.888 272 54.0 0.269 277 32.5 0.876 263 25.5 0.058
Present 204 92.2 196 59.2 202 33.2 187 33.7
Vessel invasion
Absent 159 94.3 0.255 159 58.5 0.541 156 33.3 0.817 150 25.3 0.194
Present 314 91.4 299 55.5 313 32.3 291 31.3
TNM
Stage I 77 92.1 0.566 77 52.0 0.464 77 22.1 0.147 74 23.3 0.206
Stage II 183 92.9 179 57.0 181 36.5 173 26.0
Stage III 155 94.2 151 57.6 154 34.4 142 30.3
Stage IV 75 88.0 67 59.7 73 31.5 66 39.4
BRAF mutations
Negative 87 94.3 1.000 56 65.9 0.608 33 38.4 0.641 16 19.8 0.196
Positive (V600E) 4 100 2 50.0 2 50.0 2 50.0
KRAS mutations (codon12/13 and 61)
Negative 78 96.3 0.437 51 64.6 0.217 27 34.2 0.668 17 21.8 0.411
Positive 41 93.2 31 75.6 16 38.1 6 15.4
Microsatellite Instability
Negative 102 95.3 0.986 66 65.3 0.335 38 36.5 0.321 20 20.2 0.984
Positive (MSI-L + MSI-H) 20 95.2 16 76.2 5 25.0 4 20.0
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assessed the expression and the association between
MCTs and additional proteins not previously studied
(CD147 as MCT1/4 chaperone and the glycolytic protein
marker GLUT1), to further understand the role of MCTs
in the glycolytic metabolism remodeling of primary CRC
and in metastasis.
Our results showed that most proteins studied (MCT4,
CD147 and GLUT1) were overexpressed at the plasma
membrane of CRC cells and CRC lymph node and hepatic
metastasis when compared with CRC NA tissue, with
exception of MCT1 in CRC lymph node and hepatic me-
tastasis. Here we showed that in CRC samples, MCTs were
the most frequently expressed proteins followed by CD147
and GLUT1. The MCT results are in concordance to our
previous study, in which we showed upregulation of MCT1
and MCT4 in the tumour samples, compared to NA tissue
[32]. We found that MCT1 expression was associated with
CD147 in CRC primary samples and with GLUT1 in CRC
hepatic metastasis. Expression of MCT4 was associated
with CD147 and GLUT1 in all samples. It is known that
the association of MCT1 and MCT4 with the cell surface
glycoprotein CD147 is essential for their activity and proper
expression at the plasma membrane [10, 48]. However, not
always this association prevails in cancer tissue, suggesting
the role of putative additional chaperones [9].
Most CRC cells, as many other solid tumours, rely
mostly on glycolysis to meet their energetic demands [49].
Thus, the high rates of glucose uptake are accompanied
by upregulation of glucose transporters. There are two
types of sugar transporters in gut, facilitative Na + −inde-
pendent sugar transporters (GLUT) and Na + −dependent
sugar cotransporters (SGLT), which require energy for
sugar transport. Increased expression of GLUT1 was
described in various cancer tissues, including CRC, indi-
cating that GLUT1 plays an important role in cancer and
that its expression could be useful as a marker for malig-
nant transformation [50–52]. Besides, overexpression of
SGLT1 in CRC showed a correlation with higher clinical
stages [53]. Our results showed association between
MCT1 and MCT4 and GLUT1, supporting their role in
glycolytic metabolism. To the best of our knowledge, this
is the first report on this association in the context of
CRC. Koukourakis group [31] described strong GLUT1
expression in CRC cells, although the association with
Table 6 Assessment of associations between proteins plasma membrane expression in CRC lymph node metastasis and clinical data
MCT1 MCT4 CD147 GLUT1
n Positive (%) p n Positive (%) p n Positive (%) p n Positive (%) p
Sex
Male 77 25 (32.5) 0.581 74 46 (62.2) 0.317 77 62 (91.9) 0.159 71 47 (76.7) 0.523a
Female 40 11 (27.5) 40 21 (52.5) 40 34 (82.4) 38 22 (86.4)
Age (years)
≤45 10 3 (30.0) 1.000a 8 4 (50.0) 0.715a 9 8 (75.0) 0.228a 8 5 (40.0) 0.053a
>45 107 33 (30.8) 106 63 (59.4) 108 88 (89.8) 101 64 (82.8)
Presentation
Asymptomatic 19 6 (31.6) 0.933 18 8 (44.4) 0.178 22 18 (88.9) 1.000a 16 10 (60.0) 0.109a
Symptomatic 98 30 (30.6) 96 59 (61.5) 95 78 (88.5) 93 59 (83.1)
Localization
Colon 94 28 (29.8) 0.642 91 58 (63.7) 0.032 95 81 (88.9) 0.681a 88 57 (80.7) 0.698a
Rectum 23 8 (34.8) 23 9 (39.1) 22 15 (86.7) 21 12 (75.0)
Macroscopic Appearence
Polypoid 47 14 (29.8) 0.596 47 27 (57.4) 0.534 45 36 (86.1) 0.701 45 25 (84.0) 0.500
Ulcerative 31 7 (22.6) 30 20 (66.7) 34 28 (85.7) 28 20 (70.0)
Infiltrative 13 5 (38.5) 13 6 (46.2) 12 11 (90.9) 11 6 (100.0)
Exophytic 14 6 (42.9) 13 7 (53.8) 14 12 (100.0) 14 11 (81.8)
Vilosous 1 0 (0.0) 1 0 (0.0) 1 1 (100.0) 1 1 (100.0)
CEA (ng/mL)
<5 71 21 (29.6) 0.354 67 42 (62.7) 0.434 68 56 (91.1) 0.120 65 40 (85.0) 0.237a
≥5 25 5 (20.0) 26 14 (53.8) 26 23 (78.3) 23 13 (69.2)
aComparisons were examined for statistical significance using Fisher’s exact test (when n < 5)
Martins et al. BMC Cancer  (2016) 16:535 Page 9 of 15
MCTs was not assessed. It is likely that CRC cells up-
regulate GLUT1 to increase glucose uptake and the
subsequent accumulated lactate is extruded by MCTs.
Additionally, as far as we are aware, we show for the
first time that the expression of MCTs, CD147 and
GLUT1 are also present in CRC hepatic metastasis,
suggesting the maintenance of this metabolic profile in
the invasive phenotype.
To the best of our knowledge, this is the first report
that compares the expression of these proteins in CRC
primary tumour with the respective lymph node metas-
tasis,. MCT1, CD147 and GLUT1 positivity were posi-
tively associated in CRC and lymph node metastasis,
although the expression of MCT1 was less pronounced
in the metastasis than the primary tumour, which
suggests that metabolic profile of the lymph node metas-
tasis may be different from the primary tumour. For
MCT4, the maintenance of membrane expression in
lymph node metastasis, suggests the predominance of
glycolytic metabolism, but more studies are necessary to
demonstrate this hypothesis. In studies performed in
breast cancer, MCT expression is reduced in lymph
node metastasis compared to primary tumour [54].
Lymph node metastasis are initially independent of
vascularization, relying on the stroma to provide the re-
quired nutrients [54, 55]. It seems to exist a high expres-
sion of MCT4 in the tumour stroma and an association
of this expression with a worse patient survival [55]. On
the other hand, no association with prognosis was ob-
served for epithelial MCT4 levels [55]. There is no data
Table 7 Assessment of associations between proteins plasma membrane expression in CRC lymph node metastasis and
pathological data
MCT1 MCT4 CD147 GLUT1
n Positive (%) p n Positive (%) p n Positive (%) p n Positive (%) p
Tumor size (cm)
≤4.5 67 26 (38.8) 0.065 65 38 (58.5) 0.692 68 53 (92.5) 0.492a 65 43 (76.7) 0.548a
>4.5 45 10 (22.2) 45 28 (62.2) 45 40 (87.5) 40 25 (84.0)
Histological Type
Adenocarcinoma 92 32 (34.8) 0.287 92 54 (58.7) 0.376 90 76 (88.2) 0.826a 85 58 (77.6) 0.084a
A. Mucinous 16 2 (12.5) 15 7 (46.7) 18 14 (85.7) 17 6 (100.0)
A. Invasive 6 1 (16.7) 6 5 (83.3) 6 5 (100.0) 6 4 (100.0)
Signet ring
and mucinous
3 1 (33.3) 1 1 (100.0) 3 1 (100.0) 1 1 (0.0)
Differentiation
Well-differentiated 41 18 (43.9) 0.152 40 23 (57.5) 0.493 41 36 (91.7) 0.033a 38 26 (76.9) 0.902a
Moderately-differentiated 51 13 (25.5) 50 28 (56.0) 50 43 (86.0) 47 29 (79.3)
Poorly-differentiated 23 5 (21.7) 22 15 (68.2) 23 16 (93.8) 22 13 (84.6)
Undifferentiated 1 0 (0.0) 1 0 (0.0) 2 1 (0.0) 1 1 (100.0)
Tumour Penetration
T1 2 0 (0.0) 0.408 1 0 (0.0) 0.034 2 1 (100.0) 0.665a 1 1 (100.0) 0.653a
T2 5 2 (40.0) 4 3 (75.0) 4 3 (100.0) 4 3 (66.7)
T3 101 22 (32.7) 99 62 (62.6) 101 83 (89.2) 96 61 (78.7)
T4 9 1 (11.1) 10 2 (20.0) 10 9 (77.8) 8 4 (100.0)
Spread to lymph nodes
Absent 9 4 (44.4) 0.450a 8 6 (75.0) 0.465a 10 8 (87.5) 1.000a 8 6 (100.0) 0.326a
Present 96 28 (29.2) 94 54 (57.4) 96 77 (89.6) 90 55 (76.4)
Vessel invasion
Absent 30 12 (40.0) 0.259 29 20 (69.0) 0.288 33 28 (89.3) 1.000a 30 16 (81.3) 1.000a
Present 80 23 (28.8) 78 45 (57.7) 79 62 (88.7) 73 49 (81.6)
TNM
Stage III 84 28 (33.3) 0.338 82 52 (63.4) 0.107 82 66 (92.4) 0.076 79 48 (81.3) 0.632
Stage IV 33 8 (24.2) 32 15 (46.9) 35 30 (80.0) 30 21 (76.2)
aComparisons were examined for statistical significance using Fisher’s exact test (when n < 5)
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Table 8 Assessment of associations between proteins expression in CRC hepatic metastasis and anatomopatological data from
primary tumour and clinical data from hepatic metastasis series
Anatomopatological data from Primary tumours MCT1 MCT4 CD147 GLUT1
n Positive (%) p n Positive (%) p n Positive (%) p n Positive (%) p
Localization
Colon 7 42.8 0.022 7 28.6 0.682 7 42.8 0.190 7 42.8 0.443
Rectum 38 86.8 37 43.2 36 72.2 37 59.4
CRC Stage
I + II 7 71.4 0.637 8 62.5 0.250 8 75.0 1.000 8 62.5 1.000
III + IV 34 79.4 32 37.5 31 67.7 32 56.2
Vessel invasion
Absent 4 50.0 0.681 4 50.0 0.683 4 50.0 0.560 5 80.0 0.346
Present 28 50.0 28 39.3 27 74.1 28 50.0
Clinical data from Hepatic Metastasis
Localization
One hepatic lobe 30 80.0 1.000 30 50.0 0.251 30 73.3 0.129 30 60.0 1.000
Both hepatic lobe 10 80.0 9 22.2 9 44.4 8 62.5
Size
≤5 cm 39 76.9 0.316 37 43.2 1.000 37 70.3 0.373 36 58.3 1.000
>5 cm 7 100.0 6 33.3 6 50.0 6 50.0
Fig. 3 Kaplan-Meyer survival curve of MCT1 plasma membrane expression in CRC. stage IV. The illustration represents the survival curve related to
MCT1 plasma membrane expression in CRC stage IV. Patients with negative expression of MCT1 show shorter survival (continuous line), whereas
longer survival values were obtained for patients with MCT1 positive expression (interrupted line) (p = 0.012)
Martins et al. BMC Cancer  (2016) 16:535 Page 11 of 15
in the literature for none of the proteins studied in
lymph node metastasis, so additional studies are neces-
sary to confirm and explain this observation.
Regarding the association between the proteins under
study in primary CRC and clinicopathological data, we
found that MCT1 positivity was associated with older
patients; CD147 was associated with both larger tumours
and more advanced tumour stage. Our results are sup-
ported by previous observations showing CD147 might
enhance CRC growth, thus being associated with poor
clinical prognosis [56–58]. GLUT1 expression associated
significantly with exophytic lesions, low CEA levels,
poorly-differentiated tumours, and a tendency for associ-
ation with the presence of lymph node metastasis. All of
these features, with exception of low CEA levels, are
characteristic of more aggressive tumours and poor
prognosis. These associations support previous studies
suggesting that GLUT1 may play an important role in
tumour cell survival, by promoting an adequate energy
supply [59, 60] and could be a useful biomarker for
malignant transformation [50, 60].
Regarding the association between the protein expression
in lymph node metastasis and the same clinicopathological
data, MCT4 positivity was associated with colon tumours
and more advanced tumour stage and CD147 with tumour
differentiation. MCTs and CD147 work synergistically,
increasing invasiveness and metastatic potential trough
microenvironment acidification and extracelular matrix de-
struction, via metalloproteinase induction [61–63]. Studies
with growth factors and metalloproteinases in lymph nodes
reveal expression similar to the primary tumour, suggesting
that primary tumours acquire an invasive phenotype and
that these characteristics are maintained in the metastasis
[61]. For CD147, we were unable to show that lower tumor
differentiation corresponds to higher membrane expression,
as observed in other studies [51, 64], but our sample of
poorly and undifferentiated tumours was small (n = 16 and
n = 1, respectively), which may have compromised statis-
tical power.
Data on associations between protein expression in
hepatic metastasis with the clinicopathological revealed
that MCT1 expression was associated with primary
tumour localization in colon. Association with left colon
is a poor prognosis factor since CRC located in the left
colon is associated with worse prognosis [65].
Analyzing the CRC survival curves, we observed that
MCT1 plasma membrane expression was associated
with better patient survival in stage IV, however this
association was not confirmed by multivariate analysis.
MCT1 plays a pivotal role in colon epithelial cell metab-
olism, being critical for the metabolic communication
between cells and for the transport of short chain fatty
acids (SCFA), including lactate [29, 66, 67]. Indeed, gut
microbial-derived SCFA, namely acetate, propionate and
butyrate, exert multiple beneficial effects on the colon
energy metabolism [66–69]. SCFA were demonstrated “in
vitro” and “in vivo” to induce apoptosis of CRC cells but
not of normal colon cells, protecting normal colon mu-
cosa [70, 71]. Our group has recently demonstrated that
acetate induces lysosomal membrane permeabilisation
and the release of Cathepsin D [70]. In this sense,
Table 9 Kaplan-Meyer survival curves p values
Protein
Stage MCT1 MCT4 CD147 GLUT1
Stage I 0.427 0.627 0.639 0.162
Stage II 0.249 0.596 0.300 0.302
Stage III 0.958 0.157 0.526 0.733
Stage IV 0.012 0.253 0.434 0.604
Overall 0.722 0.317 0.503 0.285
Table 10 Prognostic factors for overall survival in CRC stage IV
Overall survival
Variable Univariate analysis Multivariate analysis
HR 95 % CI p HR 95 % CI p
Age (<45 years) 2.116 0.938 – 4.774 0.071 0.898 0.271 - 2979 0.860
Localization (rectum) 0.684 0.350 – 1.447 0.267
CEA (>5 ng/mL) 2.017 1.117 – 3.641 0.020 1.834 0.946 – 3.553 0.072
Differentiation (Poorly/undifferentiated) 2.748 1.470 – 5.138 0.002 3.488 1.563 – 7.782 0.002
Spread lymph node (present) 1.156 0.638 – 2.093 0.633
Vessel invasion (present) 1.312 0.733 – 2.351 0.361
MCT1 (+) 0.394 0.186 – 0.834 0.015 0.694 0.310 – 1.597 0.390
MCT4 (+) 1.429 0.767 – 2.664 0.261
CD147 (+) 0.779 0.412 – 1.473 0.442
GLUT1 (+) 1.169 0.642 – 2.129 0.610
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overexpression of MCT1 will increase not only the uptake
of SCFA but also the transport of lactate into the CRC
cells inducing intracellular acidification [17], and conse-
quently will potentiate CRC cells apoptosis.
No significant differences were found in primary tumour,
CRC lymph node and hepatic metastasis survival curves for
the different proteins.
Conclusions
Overall, our findings support the role of MCT1, MCT4,
CD147 and GLUT1 in CRC maintenance and progression.
Moreover, since we found upregulation of these molecules
either in primary tumours or metastasis, our results also
support their exploitation as molecular targets in CRC
treatment.
Abbreviations
CEA, Carcinoembryonic antigen; CRC, Colorectal cancer; MCTs, Monocarboxylate
transporters; MSI, Microsatellite Instability; MSI-H, High MSI; MSI-L, Low MSI; MSS,
Microsatellite stable; NA, Normal adjacent epithelium; SCFA, Short chain fatty acids;
SMCTs, Sodium-coupled monocarboxylate co-transporters; TMAs, Tissue
microarrays
Acknowledgements
“Not applicable” in this section.
Funding
This work was supported by the Fundação para a Ciência e a Tecnologia
(FCT) grant ref. PTDC/SAU-FCF/104347/2008, under the scope of ‘Programa
Operacional Temático Factores de Competitividade’ (COMPETE) of ‘Quadro
Comunitário de Apoio III’ and co-financed by the Fundo Europeu De Desen-
volvimento Regional (FEDER). Ricardo Amorim was recipient of the fellowship
SFRH/BD/98002/2013, from Fundação para a Ciência e a Tecnologia (FCT
Portugal).
Availability of data and material
“Not applicable” in this section.
Authors’ contributions
SFM, AP, RMR, ALF and FB designed the structure of the study. SFM, RA, PS,
CC, SA and ALF performed the metabolic marker immunohistochemical
evaluation. HM performed the metabolic markers immunohistochemical
evaluation in normal lymph nodes. MVP and SF performed KRAS and BRAF
mutation screening and microsatellite instability analysis. FP performed CRC
TNM staging. SV and JF performed all hepatic metastasis resection and are
responsible for the clinical database of hepatic metastasis. SFM and MR
performed CRC surgery and are responsible for the CRC prospective data
bases. SFM, RA, MVP, CP and RFAC performed the statistical analysis. SFM, RA
and FB wrote the final version of the manuscript. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
“Not applicable” in this section.
Ethics approval and consent to participate
The study protocol was approved by the Ethics Committee of Hospital de
Braga. The data of CRC and lymph node metastasis series were collected
prospectively, patients were informed and signed a written consensus for
collecting data and samples collection.
Author details
1Life and Health Sciences Research Institute (ICVS), School of Health Sciences,
University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal. 2ICVS/3B’s
- PT Government Associate Laboratory, Braga/Guimarães, Portugal. 3Surgery
Department, Hospitalar Center Trás-os-Montes e Alto Douro, Chaves Unit,
Chaves, Portugal. 4Molecular Oncology Research Center, Barretos Cancer
Hospital, Barretos, São Paulo, Brazil. 5Barretos School of Health Sciences Dr.
Paulo Prata - FACISB, Barretos, São Paulo, Brazil. 6General Surgery Resident at
Braga Hospital, Braga, Portugal. 7Hepatobiliary Unit, Braga Hospital, Braga,
Portugal. 8Oncology Department, Braga Hospital, Braga, Portugal. 9Pathology
Department, Braga Hospital, Braga, Portugal. 10Coloproctology Unit, Braga
Hospital, Braga, Portugal. 11Center of Molecular and Environmental Biology
(CBMA)/Department of Biology, University of Minho, Braga, Portugal.
12Laboratory of Medical Investigation (LIM) 14, Faculty of Medicine, University
of São Paulo, São Paulo, Brazil.
Received: 23 July 2015 Accepted: 14 July 2016
References
1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of
worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;
127:2893–917.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell.
2011;144:646–74.
3. Stern R, Shuster S, Neudecker BA, Formby B. Lactate stimulates fibroblast
expression of hyaluronan and CD44: the Warburg effect revisited. Exp Cell
Res. 2002;276:24–31.
4. Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M,
Gottfried E, Schwartz S, Rothe G, Hoves S, Renner K, Timischi B, Mackensen
A, Kunz-Schughart L, Andreesen R, Krause KW, Kreutz M. Inhibitory effect of
tumor cell-derived lactic acid on human T cells. Blood. 2007;109:3812–9.
5. Ganapathy V, Thangaraju M, Prasad PD. Nutrient transporters in cancer: relevance
to Warburg hypothesis and beyond. Pharmacol Ther. 2009;121:29–40.
6. Walenta S, Schroeder T, Mueller-Klieser W. Lactate: mirror and motor of
tumor malignancy. Semin Radiat Oncol. 2004;14:267–74.
7. Walenta S, Schroeder T, Mueller-Klieser W. Lactate in solid malignant
tumors: potential basis of a metabolic classification in clinical oncology. Curr
Med Chem. 2004;11:2195–204.
8. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat
Rev Cancer. 2004;4:891–9.
9. Pinheiro C, Longatto-Filho A, Azevedo-Silva J, Casal M, Schmitt FC, Baltazar
F. Role of monocarboxylate transporters in human cancers: state of the art.
J Bioenerg Biomembr. 2012;44:127–39.
10. Pinheiro C, Reis RM, Ricardo S, Longatto-Filho A, Schmitt F, Baltazar F:
Expression of monocarboxylate transporters 1, 2 and 4 in human tumours
and their association with CD147 and CD44. J Biomed Biotechnol 2010
http://dx.doi.org/10.1155/2010/427694
11. Baltazar F, Pinheiro C, Morais-Santos F, Azevedo-Silva J, Queirós O, Preto A,
Casal M. Monocarboxylate transporters as targets and mediators in cancer
therapy response. Histol Histopathol. 2014;29:1511–24.
12. Colen CB, Seraji-Bozorgzad N, Marples B, Galloway MP, Sloan AE, Mathupala
SP. Metabolic remodeling of malignant gliomas for enhanced sensitization
during radiotherapy: an in vitro study. Neurosurgery. 2006;59:1313–23.
13. Fang J, Quinones QJ, Holman TL, Morowitz MJ, Wang K, Zhao H, Sivo F,
Maris JM, Wahl ML. The H+−linked monocarboxylate transporter (MCT1/
SLC16A1): a potential therapeutic target for high-risk neuroblastoma. Mol
Pharmacol. 2006;70:2108–15.
14. Mathupala SP, Parajuli P, Sloan AE. Silencing of monocarboxylate transporters
via small interfering ribonucleic acid inhibits glycolysis and induces cell death
in malignant glioma: an in vitro study. Neurosurgery. 2004;55:1410–9.
15. Mathupala SP, Colen CB, Parajuli P, Sloan AE. Lactate and malignant tumors:
a therapeutic target at the end stage of glycolysis. J Bioenerg Biomembr.
2007;39:73–7.
16. Schneiderhan W, Scheler M, Holzmann KH, Marx M, Gschwend JE, Bucholz
M, Gress TM, Seufferlein T, Adler G, Oswald F. CD147 silencing inhibits
lactate transport and reduces malignant potential of pancreatic cancer cells
in in vivo and in vitro models. Gut. 2009;58:1391–8.
17. Sonveaux P, Vegran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN,
Saedeleer CF, Kennedy KM, Diepart C, Jordan BF, Kelley MJ, Gallez B, Wahl
ML, Feron O, Dewhirst MW. Targeting lactate-fueled respiration selectively
kills hypoxic tumor cells in mice. J Clin Invest. 2008;118:3930–42.
18. Wahl ML, Owen JA, Burd R, Herlands RA, Nogami SS, Rodeck U, Berd D,
Leeper DB, Owen CS. Regulation of intracellular pH in human melanoma:
potential therapeutic implications. Mol Cancer Ther. 2002;1:617–28.
Martins et al. BMC Cancer  (2016) 16:535 Page 13 of 15
19. Miranda-Gonçalves V, Honavar M, Pinheiro C, Martinho O, Cordeiro M,
Bebiano G, Costa P, Reis RM, Baltazar F. Monocarboxylate transporters
(MCTs) in gliomas: expression and exploitation as therapeutic target.
Neuro-Oncology. 2013;15:172–88.
20. Morais-Santos F, Miranda-Gonçalves V, Pinheiro S, Vieira AF, Paredes J, Schmitt
FC, Baltazar F, Pinheiro C. Differential sensitivities to lactate transport inhibitors
of breast cancer cell lines. Endocr Relat Cancer. 2013;21:27–38.
21. Morais-Santos F, Granja S, Miranda-Gonçalves V, Moreira AHJ, Queirós S,
Vilaça J, Schmitt FC, Longatto-Filho A, Paredes J, Baltazar F, Pinheiro C,
Morais-Santos F, Granja S, Miranda-Gonçalves V, Moreira AHJ, Queirós S,
Vilaça J, Schmitt FC, Longatto-Filho A, Baltazar F, Pinheiro C. Targeting
lactate transport suppresses in vivo breast tumour growth. Oncotarget.
2015;6:19177–89.
22. Halestrap AP, Wilson MC. The monocarboxylate transporter family-Structure
and functional characterization. IUBMB Life. 2012;64:1–9.
23. Halestrap AP, Meredith D. The SLC16 gene family-from monocarboxylate
transporters (MCTs) to aromatic amino acid transporters and beyond.
Pflugers Arch. 2004;447:619–28.
24. Halestrap AP, Price NT. The proton-linked monocarboxylate transporter (MCT)
family: structure, function and regulation. Biochem J. 1999;343:281–99.
25. Semenza GL. Tumor metabolism: cancer cells give and take lactate. J Clin
Invest. 2008;118:3835–7.
26. Draoui N, Feron O. Lactate shuttles at a glance: from physiological
paradigms to anti-cancer treatments. Dis Model Mech. 2011;4:727–32.
27. Kirk P, Wilson MC, Heddle C, Brown MH, Barclay AN, Halestrap AP. CD147 is
tightly associated with lactate transporters MCT1 and MCT4 and facilitates
their cell surface expression. EMBO J. 2000;19:3896–904.
28. Marieb EA, Zoltan-Jones A, Li R, Misra S, Ghatak S, Cao J, Zucker S, Toole PB.
Emmprin promotes anchorage-independent growth in human mammary
carcinoma cells by stimulating hyaluronan production. Cancer Res. 2004;64:
1229–32.
29. Poole RC, Halestrap AP. Transport of lactate and other monocarboxylates
across mammalian plasma membranes. Am J Physiol. 1993;264:C761–782.
30. Tang Y, Nakada MT, Kesavan P, McCabe F, Millar H, Rafferty P, Bugelski
P, Yan L. Extracellular matrix metalloproteinase inducer stimulates tumor
angiogenesis by elevating vascular endothelial cell growth factor and
matrix metalloproteinases. Cancer Res. 2005;65:3193–9.
31. Koukourakis MI, Giatromanolaki A, Harris AL, Sivridis E. Comparison of
metabolic pathways between cancer cells and stromal cells in colorectal
carcinomas: a metabolic survival role for tumor-associated stroma. Cancer
Res. 2006;66:632–7.
32. Pinheiro C, Longatto-Filho A, Cristovam S, Ferreira L, Martins S, Pellerin L,
Rodrigues M, Alves AFV, Schimtt F, Baltazar F. Increased expression of
monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows
Arch. 2008;452:139–46.
33. Nakayama Y, Torigoe T, Inoue Y, Minagawa N, Izumi H, Kohno K, Yamaguchi
K. Prognostic significance of monocarboxylate transporter 4 expression in
patients with colorectal cancer. Exp Ther Med. 2012;3:25–30.
34. Gotanda Y, Akagi Y, Kawahara A, Kinugasa T, Yoshida T, Ryu Y, Shiratsuchi I,
Kage M, Shirouzu K. Expression of monocarboxylate transporter (MCT)-4 in
colorectal cancer and its role: MCT4 contributes to the growth of colorectal
cancer with vascular endothelial growth factor. Anticancer Res. 2013;33:2941–7.
35. Lambert DW, Wood IS, Ellis A, Shirazi-Beechey SP. Molecular changes in the
expression of human colonic nutrient transporters during the transition
from normality to malignancy. Br J Cancer. 2002;86(8):1262–9.
36. Daly K, Cuff MA, Fung F, Shirazi-Beechey SP. The importance of colonic
butyrate transport to the regulation of genes associated with colonic tissue
homoeostasis. Biochem Soc Trans. 2005;33(Pt 4):733–5.
37. Takebe K, Nio J, Morimatsu M, Karaki S, Kuwahara A, Kato I, Iwanaga T.
Histochemical demonstration of a Na (+)-coupled transporter for short-chain
fatty acids (slc5a8) in the intestine and kidney of the mouse. Biomed Res. 2005;
26(5):213–21.
38. Iwanaga T, Takebe K, Kato I, Karaki S, Kuwahara A. Cellular expression of
monocarboxylate transporters (MCT) in the digestive tract of the mouse, rat,
and humans, with special reference to slc5a8. Biomed Res. 2006;27(5):243–54.
39. Gopal E, Miyauchi S, Martin PM, Ananth S, Roon P, Smith SB, Ganapathy V.
Transport of nicotinate and structurally related compounds by human
SMCT1 (SLC5A8) and its relevance to drug transport in the mammalian
intestinal tract. Pharm Res. 2007;24(3):575–84.
40. Li H, Myeroff L, Smiraglia D, Romero MF, Pretlow TP, Kasturi L, Lutterbaugh
J, Rerko RM, Casey G, Issa JP, Willis J, Willson JK, Plass C, Markowitz SD.
SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by
methylation in human colon aberrant crypt foci and cancers. Proc Natl
Acad Sci U S A. 2003;100(14):8412–7.
41. Ganapathy V, Thangaraju M, Gopal E, Martin PM, Itagaki S, Miyauchi S,
Prasad PD. Sodium-coupled monocarboxylate transporters in normal tissues
and in cancer. AAPS J. 2008;10(1):193–9. doi:10.1208/s12248-008-9022-y.
42. Sobin LH, Wittekind C. TNM Classification of Malignant Tumours. 6th ed.
Hoboken, New Jersey: John Wiley & Sons; 2002.
43. Alves V, Pinheiro C, Morais-Santos F, Felipe-Silva A, Longatto-Filho A,
Baltazar F. Characterization of monocarboxylate transporter activity in
hepatocellular carcinoma. WJG. 2014;20:11780–7.
44. Basto D, Trovisco V, Lopes JM, Martins A, Pardal F, Soares P, Reis RM.
Mutation analysis of B-RAF gene in human gliomas. Acta Neuropathol.
2005;109:207–10.
45. Martinho O, Gouveia A, Viana-Pereira M, Silva P, Pimenta A, Reis RM, Lopes
JM. Low frequency of MAP kinase pathway alterations in KIT and PDGFRA
wild-type GISTs. Histopathology. 2009;55:53–62.
46. Viana-Pereira M, Almeida I, Sousa S, Mahler-Araújo B, Seruca R, Pimentel J,
Reis RM. Analysis of microsatellite instability in medulloblastoma. Neuro-
Oncology. 2009;11:458–67.
47. Viana-Pereira M, Lee A, Popov S, Bax DA, Al-Sarraj S, Bridges L, Stávale JN,
Hargrave D, Jones C, Reis RM. Microsatellite instability in pediatric high
grade glioma is associated with genomic profile and differential target gene
inactivation. PLoS ONE. 2011;6:e20588. doi:10.1371/journal.pone.0020588.
48. Wilson MC, Meredith D, Fox JE, Manoharan C, Davies AJ, Halestrap AP.
Basigin (CD147) is the target for organomercurial inhibition of
monocarboxylate transporter isoforms 1 and 4: the ancillary protein for the
insensitive MCT2 is EMBIGIN (gp70). J Biol Chem. 2005;280:27213–21.
49. Valk PE, Abella-Columna E, Haseman MK, Pounds TR, Tesar RD, Myers RW,
Greiss HB, Hofer GA. Whole-body PET imaging with [18 F]
fluorodeoxyglucose in management of recurrent colorectal cancer. Arch
Surg. 1999;134:503–11.
50. Haber RS, Rathan A, Weiser KR, Pritsker A, Itzkowitz SH, Bodian C, Slater G,
Weiss A, Burstein DE. GLUT1 glucose transporter expression in colorectal
carcinoma: a marker for poor prognosis. Cancer. 1998;83:34–40.
51. Jun YJ, Jang SM, Han HL, Lee KH, Jang KS, Paik SS. Clinicopathologic
significance of GLUT1 expression and its correlation with Apaf-1 in
colorectal adenocarcinomas. World J Gastroenterol. 2011;17:1866–73.
52. Younes M, Lechago LV, Lechago J. Overexpression of the human
erythrocyte glucose transporter occurs as a late event in human colorectal
carcinogenesis and is associated with an increased incidence of lymph
node metastases. Clin Cancer Res. 1996;2:1151–4.
53. Guo GF, Cai YC, Zhang B, Xu RH, Qiu HJ, Xia LP, Jiang WQ, Hu PL, Chen XX,
Zhou FF, Wang F: Overexpression of SGLT1 and EGFR in colorectal cancer
showing a correlation with the prognosis. Med Oncol. 2011, Suppl 1:S197-
203. doi: 10.1007/s12032-010-9696-8.
54. Witkiewicz AK, Whitaker-Menezes D, Dasgupta A, Philp NJ, Lin Z, Gandara R,
Sneddon S, Martinez-Outschoorn UE, Sotgia F, Lisanti MP. Using the “reverse
Warburg effect” to identify high-risk breast cancer patients: stromal MCT4
predicts poor clinical outcome in triple-negative breast cancers. Cell Cycle.
2012;11:1108–17.
55. Sotgia F, Whitaker-Menezes D, Martinez-Outschoorn UE, Flomenberg N,
Birbe RC, Witkiewicz AK, Howell A, Philp NJ, Pestell RG, Lisanti MP.
Mitochondrial metabolism in cancer metastasis: Visualizing tumor cell
mitochondria and the “reverse Warburg effect” in positive lymph node
tissue. Cell Cycle. 2012;11:1445–154.
56. Buergy D, Fuchs T, Kambakamba P, Mudduluru G, Maurer G, Post S, Tang Y,
Nakada MT, Yan L, Allgayer H. Prognostic impact of extracellular matrix
metalloprotease inducer: immunohistochemical analyses of colorectal tumors
and immunocytochemical screening of disseminated tumor cells in bone
marrow from patients with gastrointestinal cancer. Cancer. 2009;115:4667–78.
57. Stenzinger A, Wittschieber D, von Winterfeld M, Goeppert B, Kamphues C,
Weichert W, Dietel M, Rabien A, Klauschen F. High extracellular matrix
metalloproteinase inducer/CD147 expression is strongly and independently
associated with poor prognosis in colorectal cancer. Hum Pathol. 2012;43:
1471–81.
58. Zheng HC, Wang W, Xu XY, Xia P, Yu M, Sugiyama T, Takano Y. Up-
regulated EMMPRIN/CD147 protein expression might play a role in
colorectal carcinogenesis and its subsequent progression without an
alteration of its glycosylation and mRNA level. J Cancer Res Clin Oncol.
2011;137:585–96.
Martins et al. BMC Cancer  (2016) 16:535 Page 14 of 15
59. Carvalho KC, Cunha IW, Rocha RM, Ayala FR, Cajaíba MM, Begnami MD,
Vilela RS, Paiva GR, Andrade RG, Soares FA. GLUT1 expression in malignant
tumors and its use as an immunodiagnostic marker. Clinics (Sao Paulo).
2011;66:965–72.
60. Hong R. Lim SC: (1) (8) F-fluoro-2-deoxyglucose uptake on PET CT and
glucose transporter 1 expression in colorectal adenocarcinoma. World J
Gastroenterol. 2012;18:168–74.
61. Barozzi C, Ravaioli M, D’Errico A, Grazi GL, Poggioli G, Cavrini G, Mazziotti A,
Grigioni WF. Relevance of biologic markers in colorectal carcinoma: a
comparative study of a broad panel. Cancer. 2002;94:647–57.
62. Le Floch R, Chiche J, Marchiq I, Naiken T, Ilc K, Murray CM, Critchlow SE,
Roux D, Simon MP, Pouysségur J. CD147 subunit of lactate/H+ symporters
MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of
glycolytic tumors. Proc Natl Acad Sci. 2011;108:16663–8.
63. Gallagher SM, Castorino JJ, Wang D, Philp NJ. Monocarboxylate transporter
4 regulates maturation and trafficking of CD147 to the plasma membrane
in the metastatic breast cancer cell line MDA-MB-231. Cancer Res. 2007;67:
4182–9.
64. Chung FY, Huang MY, Yeh CS, Chang HJ, Cheng TL, Yen LC, Wang JY, Lin
SR. GLUT1 gene is a potential hypoxic marker in colorectal cancer patients.
BMC Cancer. 2009;9:241. doi:10.1186/1471-2407-9-241.
65. Sjo OH, Lunde OC, Nygaard K, Sandvik L, Nesbakken A. Tumour location is a
prognostic factor for survival in colonic cancer patients. Colorectal Dis. 2008;
10:33–40.
66. Goncalves P, Martel F. Butyrate and colorectal cancer: the role of butyrate
transport. Curr Drug Metab. 2013;14(9):994–1008.
67. Kim CH, Park J, Kim M. Gut microbiota-derived short-chain Fatty acids, T
cells, and inflammation. Immune Netw. 2014;14(6):277–88.
68. Kasubuchi M, et al. Dietary gut microbial metabolites, short-chain fatty acids,
and host metabolic regulation. Nutrients. 2015;7(4):2839–49.
69. Scheppach W, Bartram HP, Richter F. Role of short-chain fatty acids in the
prevention of colorectal cancer. Eur J Cancer. 1995;31A(7–8):1077–80.
70. Cuff MA, Lambert DW, Shirazi-Beechey SP. Substrate-induced regulation of
the human colonic monocarboxylate transporter, MCT1. J Physiol. 2002;539:
361–71.
71. Marques C, Oliveira CS, Alves S, Chaves SR, Coutinho OP, Côrte-Real M,
Preto A. Acetate-induced apoptosis in colorectal carcinoma cells involves
lysosomal membrane permeabilization and cathepsin D release. Cell Death
Dis. 2013;4:e507. doi:10.1038/cddis.2013.29.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Martins et al. BMC Cancer  (2016) 16:535 Page 15 of 15
